FindTrial
Sign In

Role of Tocilizumab in COVID-19 Pneumonia patients

Role of Tocilizumab in Patients with Moderate to Severe COVID-19 Pneumonia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/08/027246
Enrollment
40
Registered
2020-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

GCS Medical College Hospital and Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: RT-PCR COVID-19 Test Positive patients will be included Moderate to Severe COVID Pneumonia patients will be included

Exclusion criteria

Exclusion criteria: Patients with Active Tuberculosis, Past history of Tuberculosis, Other active suspected Viral/Fungal infection, Platelet count <50,000/ml and Absolute Pneutrophil Count <1000/ml will be excluded

Design outcomes

Primary

MeasureTime frame
Role of Tocilizumab in COVID-19 PneumoniaTimepoint: 3 months—

Secondary

MeasureTime frame
To know the efficacy of Tocilizumab in COVID-19 Pneumonia patientsTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Shaila Shah

GCS Medical College, Hospital and Research Centre

shailashah05@gmail.com9825985529

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026